Loading...
Bristol-Myers Squibb Company Ce
CELG-RI•NYSE
Healthcare
Drug Manufacturers - General
$0.03
$0.00(0.00%)
Bristol-Myers Squibb Company Ce (CELG-RI) Financial Performance & Statements
Review Bristol-Myers Squibb Company Ce’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
7.32%
↑ 7.32%
Operating Income Growth
-100.00%
↓ 100.00%
Net Income Growth
-211.50%
↓ 211.50%
Operating Cash Flow Growth
9.60%
↑ 9.60%
Operating Margin
18.45%
↑ 18.45%
Gross Margin
65.99%
↑ 65.99%
Net Profit Margin
11.38%
↑ 11.38%
ROE
31.93%
↑ 31.93%
ROIC
12.85%
↑ 12.85%
Bristol-Myers Squibb Company Ce (CELG-RI) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Bristol-Myers Squibb Company Ce stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $12.34B | $11.89B | $12.20B | $11.87B |
| Cost of Revenue | $4.81B | $2.96B | $5.40B | $2.93B |
| Gross Profit | $7.53B | $8.94B | $6.80B | $8.93B |
| Gross Profit Ratio | $0.61 | $0.75 | $0.56 | $0.75 |
| R&D Expenses | $3.22B | $2.37B | $2.29B | $2.69B |
| SG&A Expenses | $2.14B | $1.98B | $1.92B | $2.37B |
| Operating Expenses | $7.53B | $8.94B | $4.22B | $7.42B |
| Total Costs & Expenses | $12.34B | $9.60B | $9.62B | $10.35B |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $496.00M | $505.00M | $521.00M | $425.00M |
| Depreciation & Amortization | $1.88B | $2.59B | $2.56B | $2.56B |
| EBITDA | $2.55B | $4.77B | $4.37B | -$8.54B |
| EBITDA Ratio | $0.21 | $0.40 | $0.42 | $0.37 |
| Operating Income | $0.00 | $2.17B | $2.58B | $3.87B |
| Operating Income Ratio | $0.00 | $0.18 | $0.21 | $0.33 |
| Other Income/Expenses (Net) | $175.00M | -$496.00M | -$1.30B | -$2.86B |
| Income Before Tax | $175.00M | $1.68B | $1.29B | -$11.52B |
| Income Before Tax Ratio | $0.01 | $0.14 | $0.11 | -$0.97 |
| Income Tax Expense | $99.00M | $461.00M | -$398.00M | $392.00M |
| Net Income | $72.00M | $1.21B | $1.68B | -$11.91B |
| Net Income Ratio | $0.006 | $0.10 | $0.14 | -$1.004 |
| EPS | $0.04 | $0.60 | $0.83 | -$5.89 |
| Diluted EPS | $0.04 | $0.60 | $0.83 | -$5.89 |
| Weighted Avg Shares Outstanding | $2.03B | $2.03B | $2.03B | $2.02B |
| Weighted Avg Shares Outstanding (Diluted) | $2.04B | $2.03B | $2.03B | $2.02B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan